|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000167701 |
Summary for GPT |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000167701 | Gene symbol | GPT |
| Gene name | glutamic--pyruvic transaminase | |
| HGNC | 4552 | |
| Entrez ID | 2875 | |
| Gene type | protein_coding | |
| Synonyms | GPT|ALT1|GPT1 | |
| UniProtAcc | P24298 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| ENSG00000167701 | GPT | DB00114 | Pyridoxal phosphate | SmallMoleculeDrug |
| ENSG00000167701 | GPT | DB00142 | Glutamic acid | SmallMoleculeDrug |
| ENSG00000167701 | GPT | DB00160 | Alanine | SmallMoleculeDrug |
| ENSG00000167701 | GPT | DB00780 | Phenelzine | SmallMoleculeDrug |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for GPT |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| GPT | 1.43e+02 | 1.71e+00 | 5.07e-01 | 3.37e+00 | 7.63e-04 | 2.63e-03 | BLCA |
| GPT | 4.10e+02 | -1.93e+00 | 6.04e-01 | -3.19e+00 | 1.40e-03 | 8.17e-03 | ESCA |
| GPT | 4.32e+03 | -4.29e+00 | 6.86e-01 | -6.26e+00 | 3.75e-10 | 5.73e-09 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| GPT | 8.86e+02 | -1.80e+00 | 4.80e-01 | -3.74e+00 | 1.81e-04 | 4.60e-04 | KICH |
| GPT | 6.05e+02 | -1.61e+00 | 6.07e-01 | -2.65e+00 | 8.07e-03 | 2.07e-02 | READ |
Top |
Sex-biased somatic mutation for GPT |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for GPT |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg09265054 | chr8:144502755 | CGI:chr8:144500077-144501324 | promoter | 6.09e-01 | 7.86e-01 | -2.11e+00 | 3.51e-02 | 4.36e-02 | -1.76e-01 |
| BRCA | cg05241828 | chr8:144503124 | CGI:chr8:144500077-144501324 | UTR,promoter,exon,gene body | 7.35e-01 | 8.68e-01 | -2.14e+00 | 3.27e-02 | 4.25e-02 | -1.33e-01 |
| BRCA | cg25600446 | chr8:144503160 | CGI:chr8:144500077-144501324 | promoter,gene body | 6.09e-01 | 7.53e-01 | -2.09e+00 | 3.64e-02 | 4.42e-02 | -1.44e-01 |
| BRCA | cg26572973 | chr8:144503118 | CGI:chr8:144500077-144501324 | UTR,promoter,exon,gene body | 6.13e-01 | 7.28e-01 | -2.18e+00 | 2.92e-02 | 4.05e-02 | -1.15e-01 |
| KIRP | cg09265054 | chr8:144502755 | CGI:chr8:144500077-144501324 | promoter | 4.03e-01 | 2.35e-01 | 3.14e+00 | 1.70e-03 | 6.95e-03 | 1.68e-01 |
| KIRP | cg07658280 | chr8:144503107 | CGI:chr8:144500077-144501324 | UTR,promoter,exon,gene body | 5.47e-01 | 4.38e-01 | 2.68e+00 | 7.46e-03 | 1.76e-02 | 1.08e-01 |
| KIRP | cg09957864 | chr8:144503143 | CGI:chr8:144500077-144501324 | promoter,gene body | 5.10e-01 | 4.06e-01 | 2.12e+00 | 3.41e-02 | 4.08e-02 | 1.05e-01 |
| KIRP | cg11617144 | chr8:144504389 | CGI:chr8:144505007-144509987 | promoter,exon,CDS,gene body | 6.19e-01 | 5.08e-01 | 2.99e+00 | 2.79e-03 | 9.61e-03 | 1.12e-01 |
| KIRP | cg09514524 | chr8:144504416 | CGI:chr8:144505007-144509987 | promoter,exon,CDS,gene body | 7.41e-01 | 6.09e-01 | 3.88e+00 | 1.06e-04 | 8.10e-04 | 1.32e-01 |
| KIRP | cg23793500 | chr8:144502902 | CGI:chr8:144500077-144501324 | promoter | 3.99e-01 | 2.91e-01 | 2.39e+00 | 1.70e-02 | 2.82e-02 | 1.08e-01 |
| KIRP | cg15983520 | chr8:144503723 | CGI:chr8:144505007-144509987 | promoter,gene body | 5.44e-01 | 4.44e-01 | 2.82e+00 | 4.82e-03 | 1.35e-02 | 1.00e-01 |
| GBM | cg09957864 | chr8:144503143 | CGI:chr8:144500077-144501324 | promoter,gene body | 3.76e-01 | 4.88e-01 | -2.44e+00 | 1.45e-02 | 3.03e-02 | -1.12e-01 |
| KICH | cg09265054 | chr8:144502755 | CGI:chr8:144500077-144501324 | promoter | 8.77e-01 | 7.02e-01 | 2.00e+00 | 4.60e-02 | 4.83e-02 | 1.75e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUSC | cg05241828 | chr8:144503124 | CGI:chr8:144500077-144501324 | UTR,promoter,exon,gene body | 8.44e-01 | 7.28e-01 | 2.80e+00 | 5.14e-03 | 8.33e-03 | 1.16e-01 |
| LUSC | cg09957864 | chr8:144503143 | CGI:chr8:144500077-144501324 | promoter,gene body | 8.60e-01 | 7.37e-01 | 3.01e+00 | 2.57e-03 | 5.00e-03 | 1.23e-01 |
| LUSC | cg25600446 | chr8:144503160 | CGI:chr8:144500077-144501324 | promoter,gene body | 6.98e-01 | 5.62e-01 | 2.76e+00 | 5.78e-03 | 9.10e-03 | 1.36e-01 |
| LUSC | cg06110286 | chr8:144503204 | CGI:chr8:144505007-144509987 | promoter,gene body | 4.69e-01 | 3.65e-01 | 3.07e+00 | 2.13e-03 | 4.38e-03 | 1.04e-01 |
| COAD | cg00280345 | chr8:144503005 | CGI:chr8:144500077-144501324 | UTR,promoter,exon,gene body | 4.52e-01 | 5.57e-01 | -2.10e+00 | 3.58e-02 | 3.87e-02 | -1.05e-01 |
| BLCA | cg25600446 | chr8:144503160 | CGI:chr8:144500077-144501324 | promoter,gene body | 7.36e-01 | 5.90e-01 | 3.18e+00 | 1.49e-03 | 3.11e-03 | 1.46e-01 |
| BLCA | cg15685971 | chr8:144503743 | CGI:chr8:144505007-144509987 | promoter,exon,gene body | 6.90e-01 | 7.93e-01 | -2.32e+00 | 2.06e-02 | 2.50e-02 | -1.03e-01 |
| BLCA | cg18555289 | chr8:144503752 | CGI:chr8:144505007-144509987 | promoter,exon,gene body | 6.50e-01 | 7.77e-01 | -2.47e+00 | 1.36e-02 | 1.80e-02 | -1.27e-01 |
| BLCA | cg01919204 | chr8:144503766 | CGI:chr8:144505007-144509987 | promoter,exon,gene body | 6.93e-01 | 8.12e-01 | -2.77e+00 | 5.61e-03 | 8.92e-03 | -1.20e-01 |
| LIHC | cg09265054 | chr8:144502755 | CGI:chr8:144500077-144501324 | promoter | 1.40e-01 | 2.51e-01 | -5.49e+00 | 3.93e-08 | 2.43e-07 | -1.11e-01 |
| LIHC | cg25600446 | chr8:144503160 | CGI:chr8:144500077-144501324 | promoter,gene body | 3.40e-01 | 4.46e-01 | -5.28e+00 | 1.32e-07 | 6.65e-07 | -1.05e-01 |
| LIHC | cg16587265 | chr8:144502820 | CGI:chr8:144500077-144501324 | promoter | 1.96e-01 | 3.17e-01 | -6.20e+00 | 5.82e-10 | 8.67e-09 | -1.20e-01 |
| LIHC | cg14476479 | chr8:144502826 | CGI:chr8:144500077-144501324 | promoter | 2.47e-01 | 3.72e-01 | -6.09e+00 | 1.16e-09 | 1.46e-08 | -1.25e-01 |
| LIHC | cg23793500 | chr8:144502902 | CGI:chr8:144500077-144501324 | promoter | 2.35e-01 | 3.75e-01 | -5.78e+00 | 7.45e-09 | 6.27e-08 | -1.40e-01 |
| LIHC | cg26572973 | chr8:144503118 | CGI:chr8:144500077-144501324 | UTR,promoter,exon,gene body | 3.79e-01 | 4.87e-01 | -5.39e+00 | 6.93e-08 | 3.88e-07 | -1.08e-01 |
| LIHC | cg19352605 | chr8:144503247 | CGI:chr8:144505007-144509987 | promoter,gene body | 2.57e-01 | 3.81e-01 | -5.81e+00 | 6.34e-09 | 5.51e-08 | -1.24e-01 |
| LIHC | cg15685971 | chr8:144503743 | CGI:chr8:144505007-144509987 | promoter,exon,gene body | 4.10e-01 | 5.21e-01 | -5.97e+00 | 2.43e-09 | 2.58e-08 | -1.11e-01 |
| LIHC | cg24811740 | chr8:144504154 | CGI:chr8:144505007-144509987 | UTR,promoter,exon,gene body | 3.01e-01 | 4.15e-01 | -5.76e+00 | 8.35e-09 | 6.87e-08 | -1.14e-01 |
| KIRP | cg20545776 | chr8:144503813 | CGI:chr8:144505007-144509987 | promoter,exon,gene body | 3.69e-01 | 4.99e-01 | -4.80e+00 | 1.56e-06 | 7.91e-06 | -1.30e-01 |
| KIRP | cg09265054 | chr8:144502755 | CGI:chr8:144500077-144501324 | promoter | 2.35e-01 | 4.32e-01 | -4.41e+00 | 1.04e-05 | 3.84e-05 | -1.97e-01 |
| KIRP | cg07658280 | chr8:144503107 | CGI:chr8:144500077-144501324 | UTR,promoter,exon,gene body | 4.38e-01 | 5.39e-01 | -2.88e+00 | 3.98e-03 | 5.87e-03 | -1.01e-01 |
| KIRP | cg23793500 | chr8:144502902 | CGI:chr8:144500077-144501324 | promoter | 2.91e-01 | 3.95e-01 | -3.50e+00 | 4.63e-04 | 9.49e-04 | -1.04e-01 |
| KIRP | cg00280345 | chr8:144503005 | CGI:chr8:144500077-144501324 | UTR,promoter,exon,gene body | 4.17e-01 | 6.22e-01 | -4.37e+00 | 1.26e-05 | 4.54e-05 | -2.05e-01 |
| KIRP | cg15983520 | chr8:144503723 | CGI:chr8:144505007-144509987 | promoter,gene body | 4.44e-01 | 5.92e-01 | -4.01e+00 | 6.05e-05 | 1.70e-04 | -1.48e-01 |
| KIRP | cg18555289 | chr8:144503752 | CGI:chr8:144505007-144509987 | promoter,exon,gene body | 3.98e-01 | 4.99e-01 | -3.29e+00 | 9.97e-04 | 1.82e-03 | -1.02e-01 |
| KIRP | cg01919204 | chr8:144503766 | CGI:chr8:144505007-144509987 | promoter,exon,gene body | 3.90e-01 | 4.94e-01 | -3.44e+00 | 5.79e-04 | 1.15e-03 | -1.05e-01 |
| ESCA | cg20545776 | chr8:144503813 | CGI:chr8:144505007-144509987 | promoter,exon,gene body | 6.16e-01 | 4.59e-01 | 2.58e+00 | 9.85e-03 | 3.61e-02 | 1.57e-01 |
| ESCA | cg09265054 | chr8:144502755 | CGI:chr8:144500077-144501324 | promoter | 6.33e-01 | 2.75e-01 | 2.77e+00 | 5.61e-03 | 3.47e-02 | 3.58e-01 |
| ESCA | cg07658280 | chr8:144503107 | CGI:chr8:144500077-144501324 | UTR,promoter,exon,gene body | 7.86e-01 | 5.64e-01 | 2.34e+00 | 1.91e-02 | 4.01e-02 | 2.22e-01 |
| ESCA | cg05241828 | chr8:144503124 | CGI:chr8:144500077-144501324 | UTR,promoter,exon,gene body | 7.25e-01 | 4.99e-01 | 2.24e+00 | 2.49e-02 | 4.21e-02 | 2.27e-01 |
| ESCA | cg09957864 | chr8:144503143 | CGI:chr8:144500077-144501324 | promoter,gene body | 7.37e-01 | 4.70e-01 | 2.52e+00 | 1.17e-02 | 3.69e-02 | 2.67e-01 |
| ESCA | cg25600446 | chr8:144503160 | CGI:chr8:144500077-144501324 | promoter,gene body | 5.84e-01 | 4.01e-01 | 2.17e+00 | 2.97e-02 | 4.37e-02 | 1.83e-01 |
| ESCA | cg11617144 | chr8:144504389 | CGI:chr8:144505007-144509987 | promoter,exon,CDS,gene body | 8.55e-01 | 5.85e-01 | 2.25e+00 | 2.42e-02 | 4.19e-02 | 2.70e-01 |
| ESCA | cg09514524 | chr8:144504416 | CGI:chr8:144505007-144509987 | promoter,exon,CDS,gene body | 9.32e-01 | 6.77e-01 | 2.19e+00 | 2.82e-02 | 4.32e-02 | 2.54e-01 |
| ESCA | cg16587265 | chr8:144502820 | CGI:chr8:144500077-144501324 | promoter | 3.70e-01 | 2.51e-01 | 1.99e+00 | 4.71e-02 | 4.87e-02 | 1.18e-01 |
| ESCA | cg14476479 | chr8:144502826 | CGI:chr8:144500077-144501324 | promoter | 4.84e-01 | 3.24e-01 | 2.41e+00 | 1.59e-02 | 3.86e-02 | 1.59e-01 |
| ESCA | cg23793500 | chr8:144502902 | CGI:chr8:144500077-144501324 | promoter | 5.53e-01 | 3.46e-01 | 2.31e+00 | 2.07e-02 | 4.06e-02 | 2.06e-01 |
| ESCA | cg26572973 | chr8:144503118 | CGI:chr8:144500077-144501324 | UTR,promoter,exon,gene body | 5.60e-01 | 4.26e-01 | 2.18e+00 | 2.90e-02 | 4.34e-02 | 1.35e-01 |
| ESCA | cg01919204 | chr8:144503766 | CGI:chr8:144505007-144509987 | promoter,exon,gene body | 6.39e-01 | 4.85e-01 | 2.02e+00 | 4.39e-02 | 4.78e-02 | 1.55e-01 |
| ESCA | cg11211951 | chr8:144504357 | CGI:chr8:144505007-144509987 | promoter,exon,CDS,gene body | 8.18e-01 | 6.61e-01 | 2.15e+00 | 3.12e-02 | 4.42e-02 | 1.57e-01 |
| CHOL | cg11617144 | chr8:144504389 | CGI:chr8:144505007-144509987 | promoter,exon,CDS,gene body | 8.00e-01 | 5.15e-01 | 2.58e+00 | 9.87e-03 | 2.15e-02 | 2.85e-01 |
| CHOL | cg09514524 | chr8:144504416 | CGI:chr8:144505007-144509987 | promoter,exon,CDS,gene body | 8.86e-01 | 5.50e-01 | 2.65e+00 | 7.96e-03 | 1.92e-02 | 3.36e-01 |
| CHOL | cg11211951 | chr8:144504357 | CGI:chr8:144505007-144509987 | promoter,exon,CDS,gene body | 8.17e-01 | 6.57e-01 | 2.29e+00 | 2.23e-02 | 3.24e-02 | 1.59e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg09265054 | chr8:144502755 | CGI:chr8:144500077-144501324 | promoter | 6.09e-01 | 4.11e-01 | 5.38e+00 | 7.50e-08 | 1.55e-07 | 1.98e-01 |
| BRCA | cg07658280 | chr8:144503107 | CGI:chr8:144500077-144501324 | UTR,promoter,exon,gene body | 8.01e-01 | 6.82e-01 | 6.81e+00 | 9.94e-12 | 2.83e-11 | 1.19e-01 |
| BRCA | cg05241828 | chr8:144503124 | CGI:chr8:144500077-144501324 | UTR,promoter,exon,gene body | 7.35e-01 | 5.85e-01 | 6.26e+00 | 3.81e-10 | 9.58e-10 | 1.51e-01 |
| BRCA | cg09957864 | chr8:144503143 | CGI:chr8:144500077-144501324 | promoter,gene body | 7.50e-01 | 5.97e-01 | 6.69e+00 | 2.27e-11 | 6.26e-11 | 1.53e-01 |
| BRCA | cg25600446 | chr8:144503160 | CGI:chr8:144500077-144501324 | promoter,gene body | 6.09e-01 | 4.78e-01 | 5.79e+00 | 6.91e-09 | 1.57e-08 | 1.31e-01 |
| KIRC | cg20545776 | chr8:144503813 | CGI:chr8:144505007-144509987 | promoter,exon,gene body | 4.49e-01 | 5.77e-01 | -3.07e+00 | 2.11e-03 | 6.63e-03 | -1.28e-01 |
| KIRC | cg07658280 | chr8:144503107 | CGI:chr8:144500077-144501324 | UTR,promoter,exon,gene body | 5.70e-01 | 6.97e-01 | -2.32e+00 | 2.06e-02 | 2.75e-02 | -1.27e-01 |
| KIRC | cg16587265 | chr8:144502820 | CGI:chr8:144500077-144501324 | promoter | 3.16e-01 | 4.66e-01 | -2.98e+00 | 2.91e-03 | 7.97e-03 | -1.50e-01 |
| KIRC | cg15685971 | chr8:144503743 | CGI:chr8:144505007-144509987 | promoter,exon,gene body | 5.42e-01 | 6.67e-01 | -3.14e+00 | 1.71e-03 | 5.91e-03 | -1.25e-01 |
| KIRC | cg18555289 | chr8:144503752 | CGI:chr8:144505007-144509987 | promoter,exon,gene body | 5.27e-01 | 6.36e-01 | -2.36e+00 | 1.81e-02 | 2.52e-02 | -1.09e-01 |
| KIRC | cg01919204 | chr8:144503766 | CGI:chr8:144505007-144509987 | promoter,exon,gene body | 5.13e-01 | 6.50e-01 | -2.83e+00 | 4.66e-03 | 1.05e-02 | -1.37e-01 |
| THCA | cg05241828 | chr8:144503124 | CGI:chr8:144500077-144501324 | UTR,promoter,exon,gene body | 7.92e-01 | 8.99e-01 | -2.01e+00 | 4.43e-02 | 4.56e-02 | -1.08e-01 |
| THCA | cg26572973 | chr8:144503118 | CGI:chr8:144500077-144501324 | UTR,promoter,exon,gene body | 5.70e-01 | 6.76e-01 | -4.20e+00 | 2.72e-05 | 1.04e-04 | -1.06e-01 |
| HNSC | cg15983520 | chr8:144503723 | CGI:chr8:144505007-144509987 | promoter,gene body | 8.40e-01 | 7.05e-01 | 2.49e+00 | 1.28e-02 | 2.13e-02 | 1.35e-01 |
| HNSC | cg24811740 | chr8:144504154 | CGI:chr8:144505007-144509987 | UTR,promoter,exon,gene body | 5.03e-01 | 3.64e-01 | 2.56e+00 | 1.06e-02 | 1.92e-02 | 1.39e-01 |
| COAD | cg09265054 | chr8:144502755 | CGI:chr8:144500077-144501324 | promoter | 4.22e-01 | 1.99e-01 | 3.02e+00 | 2.56e-03 | 5.83e-03 | 2.22e-01 |
| COAD | cg15983520 | chr8:144503723 | CGI:chr8:144505007-144509987 | promoter,gene body | 5.98e-01 | 4.79e-01 | 2.69e+00 | 7.08e-03 | 1.22e-02 | 1.19e-01 |
| KIRP | cg06110286 | chr8:144503204 | CGI:chr8:144505007-144509987 | promoter,gene body | 3.46e-01 | 2.36e-01 | 1.99e+00 | 4.61e-02 | 4.72e-02 | 1.10e-01 |
Top |
Exon skipping events with PSI in TCGA for GPT |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for GPT |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for GPT |
| TFs related to GPT. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BRCA | GLIS2 | GPT | 3.06e+00 | 5.23e-03 | 4.48e+00 | 9.84e-01 | Female-biased |
| BRCA | NHLH1 | GPT | 2.98e+00 | 5.44e-03 | 4.38e+00 | 9.82e-01 | Female-biased |
| BRCA | PATZ1 | GPT | 2.70e+00 | 2.68e-03 | 4.32e+00 | 9.84e-01 | Female-biased |
| BRCA | PLAG1 | GPT | 2.81e+00 | 2.97e-03 | 4.41e+00 | 9.85e-01 | Female-biased |
| BRCA | PLAGL2 | GPT | 3.20e+00 | 2.57e-03 | 4.85e+00 | 9.92e-01 | Female-biased |
| BRCA | SPZ1 | GPT | 2.89e+00 | 3.73e-03 | 4.41e+00 | 9.85e-01 | Female-biased |
| BRCA | TCF3 | GPT | 2.81e+00 | 3.02e-03 | 4.39e+00 | 9.85e-01 | Female-biased |
| BRCA | TFAP2A | GPT | 2.96e+00 | 3.15e-03 | 4.53e+00 | 9.88e-01 | Female-biased |
| BRCA | TFAP2C | GPT | 2.99e+00 | 2.76e-03 | 4.61e+00 | 9.89e-01 | Female-biased |
| BRCA | ZIC2 | GPT | 2.70e+00 | 3.18e-03 | 4.27e+00 | 9.82e-01 | Female-biased |
| BRCA | ZNF101 | GPT | 2.88e+00 | 3.85e-03 | 4.39e+00 | 9.84e-01 | Female-biased |
| BRCA | ZNF141 | GPT | 2.76e+00 | 1.65e-03 | 4.54e+00 | 9.89e-01 | Female-biased |
| BRCA | ZNF28 | GPT | 2.73e+00 | 1.67e-03 | 4.51e+00 | 9.89e-01 | Female-biased |
| BRCA | ZNF415 | GPT | 2.72e+00 | 3.26e-03 | 4.28e+00 | 9.82e-01 | Female-biased |
| BRCA | ZNF431 | GPT | 2.94e+00 | 4.13e-03 | 4.43e+00 | 9.84e-01 | Female-biased |
| BRCA | ZNF506 | GPT | 2.93e+00 | 5.67e-03 | 4.31e+00 | 9.80e-01 | Female-biased |
| BRCA | ZNF619 | GPT | 2.70e+00 | 2.92e-03 | 4.30e+00 | 9.83e-01 | Female-biased |
| BRCA | ZNF692 | GPT | 3.07e+00 | 7.01e-03 | 4.39e+00 | 9.81e-01 | Female-biased |
| BRCA | ZNF740 | GPT | 2.73e+00 | 2.62e-03 | 4.36e+00 | 9.85e-01 | Female-biased |
| BRCA | ZNF816 | GPT | 2.68e+00 | 2.78e-03 | 4.29e+00 | 9.83e-01 | Female-biased |
| BRCA | ZNF891 | GPT | 2.66e+00 | 1.66e-03 | 4.44e+00 | 9.87e-01 | Female-biased |
| GPT related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for GPT |
| RBPs related to ES in GPT. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| GPT related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs35303095 | chr8:140277329:A:G | - | 0.100787974796399 | 0.0102737140260431 | LIHC | Male-baised eQTL |
| rs56350727 | chr8:140274228:A:G | - | 0.0940293787263791 | 0.0195999326270678 | LIHC | Male-baised eQTL |
| rs13276843 | chr8:140277567:C:A | - | 0.0949558545498058 | 0.0197033157685639 | LIHC | Male-baised eQTL |
| rs1480818 | chr8:135069461:C:G | - | 0.0615553097433776 | 0.0292177187076383 | COAD | Male-baised eQTL |
| rs6986960 | chr8:135073775:C:T | - | 0.0615409712540395 | 0.0292838587354403 | COAD | Male-baised eQTL |
| rs6578120 | chr8:135074433:C:T | - | 0.0615409712540395 | 0.0292838587354403 | COAD | Male-baised eQTL |
| rs899925 | chr8:135070672:C:T | - | 0.0613116804039427 | 0.0314897604409275 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000167701 |
| CpG Site: cg16587265 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.481847938858837 | |
 | Gene ID: ENSG00000167701 |
| CpG Site: cg17869161 | |
| Position to Gene: gene,exon,promoter | |
| Male Effect: - | |
| Female Effect: -0.481847938858837 | |
 | Gene ID: ENSG00000167701 |
| CpG Site: cg02185216 | |
| Position to Gene: gene,enhancer | |
| Male Effect: - | |
| Female Effect: -0.481847938858837 | |
 | Gene ID: ENSG00000167701 |
| CpG Site: cg21040069 | |
| Position to Gene: gene,exon,enhancer,UTR | |
| Male Effect: - | |
| Female Effect: -0.481847938858837 | |
 | Gene ID: ENSG00000167701 |
| CpG Site: cg09265054 | |
| Position to Gene: promoter | |
| Male Effect: -0.134057442325037 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg09265054 | chr8:144502755 | promoter | -0.134057442325037 | 1.92397559352491e-12 | -0.49078768583298116 | 6.414992425895976e-15 | LUAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg16587265 | chr8:144502820 | promoter | -0.481847938858837 | 2.74781939640998e-38 | -0.9749372698017156 | 8.363923388480463e-45 | LAML |
| cg17869161 | chr8:144503990 | gene,exon,promoter | -0.481847938858837 | 2.74781939640998e-38 | -0.9749372698017156 | 8.363923388480463e-45 | LAML |
| cg02185216 | chr8:144505803 | gene,enhancer | -0.481847938858837 | 2.74781939640998e-38 | -0.9749372698017156 | 8.363923388480463e-45 | LAML |
| cg21040069 | chr8:144507027 | gene,exon,enhancer,UTR | -0.481847938858837 | 2.74781939640998e-38 | -0.9749372698017156 | 8.363923388480463e-45 | LAML |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of GPT |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000167701 | GPT | C0015695 | Fatty Liver | 1 | CTD_human |
| ENSG00000167701 | GPT | C0019193 | Hepatitis, Toxic | 2 | CTD_human |
| ENSG00000167701 | GPT | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
| ENSG00000167701 | GPT | C0023895 | Liver diseases | 1 | CTD_human |
| ENSG00000167701 | GPT | C0035126 | Reperfusion Injury | 1 | CTD_human |
| ENSG00000167701 | GPT | C0086565 | Liver Dysfunction | 1 | CTD_human |
| ENSG00000167701 | GPT | C0860207 | Drug-Induced Liver Disease | 2 | CTD_human |
| ENSG00000167701 | GPT | C1262760 | Hepatitis, Drug-Induced | 2 | CTD_human |
| ENSG00000167701 | GPT | C2711227 | Steatohepatitis | 1 | CTD_human |
| ENSG00000167701 | GPT | C3658290 | Drug-Induced Acute Liver Injury | 2 | CTD_human |
| ENSG00000167701 | GPT | C4277682 | Chemical and Drug Induced Liver Injury | 2 | CTD_human |
| ENSG00000167701 | GPT | C4279912 | Chemically-Induced Liver Toxicity | 2 | CTD_human |
